Stana Moisescu of Teva Pharmaceuticals Romania shares her insights on how to overcome unpredictability and inconsistency at the government level in Romania and why there needs to be a change in the country’s clawback tax. Moisescu shares news of upcoming launches of both innovative and generic products and the optimisation process that Teva has carried out over the last two years.
Romania can be seen as a very attractive market for the pharmaceutical industry: a population of 20 million, high levels of unmet medical need and as a result a constantly increasing consumption rate
